RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer (RASANC)

Association des Gastroentérologues Oncologues

Status: Unknown

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT02502656

RASANC

Details and patient eligibility

About

This study will evaluate the concordance of RAS mutation detection between the results obtained from circulating tumor DNA and those obtained with the "standard" method (testing from tumor tissue).

Enrollment: 425 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pathologically confirmed metachronous or synchronous metastatic colorectal cancer
• No prior chemotherapy with the exception of adjuvant chemotherapy completed ≥ 6 months prior to enrollment
• Signed written informed consent obtained prior to any study specific screening procedures
• Patients willing to provide a blood sample for Translational Research

Exclusion criteria

• No tumor block available
• Previous malignancy in the last 5 years
• Medical, sociological, psychological or legal conditions that would not permit the patient to sign informed consent